Search Bar & Filters
Found 3 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the pharmacokinetic comparability between TAK-881 and HYQVIA when given as subcutaneous injections for maintenance therapy in adults with chronic inflammatory demyelinating polyradiculoneuropathy CIDP. This phase 3 trial focuses on participants who have been receiving intravenous or subcutaneous immunoglobulin treatments and aims to compare these two treatments in terms of how the body absorbs and processes them. The study includes several phases starting with screening and possibly a ramp-up phase for those switching treatments. Participants already on HYQVIA go directly to that treatment phase, which lasts 18 to 20 weeks depending on dosing intervals. Then all participants switch to TAK-881 for 24 weeks. After this, an extension phase allows continued treatment for up to 3 years, with home infusions permitted and clinic visits spaced between 12 and 24 weeks. Treatments are given by subcutaneous infusion using specialized needle sets. Participants will visit the clinic every 3 or 4 weeks during the initial phases to undergo assessments including blood sampling to measure immunoglobulin G levels at various time points. The study also tracks clinical disability scores, hand grip strength, muscle strength, and adverse events over time. Safety and treatment tolerability are closely monitored throughout the trial. Total participation may last several years including the extension phase.
Actively Recruiting
Researchers are evaluating the effectiveness of riliprubart compared to the usual treatment of intravenous immunoglobulin IVIg in adults with Chronic Inflammatory Demyelinating Polyneuropathy CIDP who are currently receiving maintenance IVIg therapy. This Phase 3 randomized study aims to understand how well riliprubart works in this group over a study duration of up to 109 weeks, including screening, treatment, and follow-up periods. Participants are randomly assigned to one of two groups one group receives riliprubart along with a placebo IVIg infusion for 24 weeks, followed by an open-label extension phase with riliprubart for another 24 weeks the other group continues IVIg treatment with a placebo riliprubart for 24 weeks, then also enters the open-label riliprubart extension. Treatments are given as intravenous or subcutaneous infusions, and dosing follows established maintenance regimens. During the study, participants will have regular assessments to monitor their response to treatment. These include measuring disability and fatigue scales, grip strength, and relapse rates from baseline through various time points up to week 109. Safety is monitored by tracking treatment-emergent adverse events and antibody development. Participants are followed closely through scheduled visits to evaluate changes in their condition and overall health status throughout the study.
Actively Recruiting
Researchers are conducting a Phase 3, randomized, open-label study comparing two ways of giving the drug frexalimabby subcutaneous under the skin injection every 4 weeks versus intravenous IV infusion every 4 weeksin adults aged 18 to 60 years with relapsing multiple sclerosis RMS or non-relapsing secondary progressive multiple sclerosis nrSPMS. The study aims to evaluate the pharmacokinetics, safety, and efficacy of these two administration methods in this population. Participants will receive frexalimab either through an IV infusion or by subcutaneous injection using an on-body delivery system OBDS, with the option for home self-administration starting after appropriate training in Part B of the study. The treatment period for Parts A and B combined lasts 48 weeks 12 months, with an optional Part C continuing until a long-term safety study begins. Scheduled visits occur monthly between weeks 4 and 24, then every 1 to 3 months in Part B, and every 6 months in Part C. Participants discontinuing treatment early will have additional follow-up visits. During the study, participants will undergo regular on-site visits for drug administration and monitoring. Researchers will collect blood samples to assess drug levels and immune responses, perform MRI scans to track brain lesions, and monitor safety through adverse event reporting and laboratory tests. The studys main outcomes include drug concentration measurements up to week 24 and safety and efficacy assessments up to week 96. Follow-up after treatment ends will continue for 6 months to observe any ongoing effects.